Slapak, Christopher A.

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

Simon, G. R., Ilaria, R. L., Sovak, M. A., Williams, C. C., Haura, E. B., Cleverly, A. L., Sykes, A. K., Wagner, M. M., de Alwis, D. P., Slapak, C. A., et al. (2011) · Cancer Chemotherapy and Pharmacology

Cancer therapeutics and mechanismsStatistical Methods in Clinical Trials

Cited by 19

Phase 1 study of a hepcidin antagonist, LY2787106, in cancer-associated anemia

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Tiu, R. V., Wang, X., Callies, S., Cox, J., Tuttle, J. L., et al. (2015) · Blood

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 6